Search

Malignome im Bereich des Uterus Das Manual zu den Malignomen des Corpus uteri liegt aktuell in der 4. Auflage (2022) vor und beinhaltet Empfehlungen zur Diagnostik, Therapie und Nachsorge von Malignomen im Bereich des Uterus. Die Inhalte wurden von interdisziplinär zusammengesetzten Expertenteams erarbeitet und diskutiert. Nun sind sie in diesem Manual als Empfehlungen für die Praxis nachzulesen. Das Buch ist hochaktuell, leitliniengerecht und bietet darüber hinaus einen Austausch an Erfahrungen. Das Expertenwissen und die damit verbundene klinische Erfahrung wird somit einer breiten Öffentlichkeit zur Verfügung gestellt. Die Versorgung der Patienten soll auf diese Weise verbessert werden. Das Buch beinhaltet folgende Bereiche: Epidemiologie, Früherkennung und prätherapeutische Diagnostik, Bildgebende Diagnostik, Histopathologie, Therapie der Endometriumhyperplasie, Fertilitätserhaltende Therapie, Operative Therapie, Uterussarkome, Radioonkologische Behandlung, Adjuvante medikamentöse Therapie, Therapie in der Rezidiv- und Palliativsituation, Nachsorge.

友人や家族にもなかなか相談しづらい生理や子宮のはなし。「いつもと違う」と感じたら，何か病気のサインかもしれません。 「最近,生理痛がひどくなっている気がする…」「子宮頸がん検診はどのくらいの頻度で受診すればいいの？」など，子宮に関するさまざまな疑問に，産婦人科の専門医がお答えします。 近年，女性のライフスタイルの多様化により，卵胞ホルモン（エストロゲン)が原因となる子宮の病気が増加傾向にあります。 痛み止めやピルなど，対症療法だけですむ場合もありますが，子宮内膜症は不妊症やがんの原因となるため，専門医の診察が必要です。 また，子宮頸がんはセックスによるウイルス感染が発症の原因となります。定期的な検診が不可欠です。 本書をきっかけにして，ご自身の子宮について，健康について,あらためてよく考えてみませんか？

There are more than 63,000 new cases of uterine and endometrial cancer each year in the United States, up from approximately 41,000 when the first edition of Uterine Cancer was published in 2009. A book focusing on these cancers was timely, with emergent sophistication in diagnosis increasingly impacting clinical decision-making. However, five years later, the need for an updated book on this topic is even stronger as oncologists recognize opportunities to impact the outcome on women that are increasingly diagnosed with these malignancies. Uterine Cancer: Screening, Diagnosis, and Treatment, Second Edition, ​part of the Current Clinical Oncology series, enhances the awareness on this somewhat neglected area of therapeutics, helping to integrate targeted therapies into the management of women with uterine cancer. Written by experts in the field in a highly practical and comprehensive manner, it is a must-have for all gynecological residents and fellows, as well as gynecological oncologists, medical oncologists, radiation oncologists, and family practice doctors who wish to provide their patients with the best possible care.

This book focuses on precursor lesions, borderline lesions, and early carcinomas of female-specific organs from the standpoint of pathology. In 2012, WHO Classification of Tumours of the Breast was revised and subsequently, in 2014, the WHO Classification of Tumours of Female Reproductive Organs was revised. In these latest versions, several new concepts are addressed that were not described in the previous editions, and many of them are related to the awareness of the specific pathogenesis of tumors in female patients. Although some of these issues are still controversial, several paradigm shifts should be understood by medical scientists. Thus researchers, diagnostic pathologists, and clinicians must share current information about what is taking place in the field and what the next issue to resolve is. This volume greatly broadens the reader's understanding of the new concepts and paradigm shifts, as it includes information on how to diagnose and makedifferential diagnoses on a practical basis and also provides a thorough explanation of the molecular–clinicopathologic basis of the new concepts. The book thus benefits gynecologists, breast surgeons, gynecologic–medical oncologists, and cytotechnologists.

This text provides a comprehensive review for practicing pathologists to understand the molecular biology, diagnostics, and predictive markers and implications for therapy of uterine cancer. While molecular based therapeutic strategies for uterine cancer are not as well developed as for some other organ sites, these are the most common gynecologic malignancies and there have been many important recent developments that are discussed in this volume. Comprehensive chapters address essential information about endometrial carcinoma, uterine mesenchymal tumors, and cervical carcinoma and include the pathogenesis of carcinoma and discuss molecular based classification, biomarkers, therapy, prevention, and hereditary cancers of the uterus. Precision Molecular Pathology of Uterine Cancer is a unique and one of a kind resource for practicing pathologists, pathologists in training and gynecologists.

This book offers clear, up-to-date guidance on how to report cytologic findings in cervical, vaginal and anal samples in accordance with the 2014 Bethesda System Update. The new edition has been expanded and revised to take into account the advances and experience of the past decade. A new chapter has been added, the terminology and text have been updated, and various terminological and morphologic questions have been clarified. In addition, new images are included that reflect the experience gained with liquid-based cytology since the publication of the last edition in 2004. Among more than 300 images, some represent classic examples of an entity while others illustrate interpretative dilemmas, borderline cytomorphologic features or mimics of epithelial abnormalities. The Bethesda System for Reporting Cervical Cytology, with its user-friendly format, is a “must have” for pathologists, cytopathologists, pathology residents, cytotechnologists, and clinicians.

For the Editors, the task of writing a Preface is most satisfying. It represents the completion of the book and a moment of reflection on whether the whole is more than the sum of all the parts. And also, one must reflect on how this book is likely to be utilized in this era of rapid communications. The Editors first met in May 2003 at a stimulating Italian symposium on endometrial cancer (organizers Drs. Luigi Frigerio, Roberto Grassi and Andrea Lissoni, with participation of the deans of Italian Gynecologic Oncology, Ugo Bianchi and Constantino Mangioni) that took place at Bergamo and Caravaggio. The impressive gains in biology and clinical trials were further discussed by the two editors and others that are co-authors in this venture on this side of the Atlantic at a 2004 Educational Session at the American Society of Clinical Oncology (ASCO). The pace of progress in various aspects of management of uterine cancer was no- worthy, not only was tumor biology fueling novel hypotheses such as questioning the mesenchymal origin of carcinosarcomas, but knowledge of molecular pathways was beginning to be applied as prognostic and as predictive factors portending benefit from systemic therapies. Surgical staging and sensitive imaging provided the underpinning for refining our treatment algorithms. Finally, a role for che- therapy had finally become established, principally through phase III studies c- paring chemotherapy to radiation in mostly locally advanced stages III and IV that had undergone resection.

Die seltenen uterinen Sarkome und malignen Mischtumoren sind häufig ein Zufallsbefund. Neben nur wenigen aussagekräftigen Studien existieren keine definierten Therapiestandards und Leitlinien. Wegen der schwierigen Abgrenzung zu den Sarkomen und malignen Mischtumoren wurden auch die mesenchymalen Tumoren mit auffälligen klinischen Eigenschaften, einem potentiell klinisch malignen Verhalten und einem unsicherem malignen Potential aber auch gutartige Mischtumoren in die Publikation aufgenommen. Für jede Entität erfolgt eine detaillierte Besprechung zur Epidemiologie, Ätiologie und Pathogenese. Besonderer Wert wird auf die makro- und mikroskopische Charakterisierung, die Prognose sowie die Diagnostik und Differenzialdiagnose mit ihren Fallstricken und Fehlerquellen gelegt. Die klar formulierten Therapieempfehlungen behandeln jeweils auf den Uterus begrenzte, fortgeschrittene, rezidivierte und metastasierte Tumoren. Die Möglichkeiten der Operation, der Bestrahlung, der neoadjuvanten, adjuvanten sowie palliativen Hormon- und Chemotherapie und Empfehlungen zur Nachsorge werden umfassend und kritisch dargestellt. Trotz der vergleichsweise ausführlichen pathologisch-anatomischen Beschreibung, soll dieses Buch mit über 200 hochwertigen, vierfarbigen Abbildungen und einem umfassenden aktuellen Literaturverzeichnis dennoch ein Leitfaden zur Entscheidungsfindung für den klinisch und ambulant tätigen Gynäkologen und Onkologen zu sein. Für die aufgeführten Tumorgruppen existiert gegenwärtig keine weitere zusammenfassende Monographie.

The only guide to provide comprehensive coverage of the management of endometrial cancer, as well as cancers in, on, and around the uterus. Studies the impact of diagnostic tools, imaging techniques, and sampling procedures in the evaluation and management of various cancers. Discusses late and advanced stage treatments including radiation and surg